Skip to Main Content
  • Login
  • Contact Us
  • Donate

NANETS

  • About
    • Mission
    • Board of Directors
    • Committees
    • NANETS Presidents
    • Lifetime Achievement
    • Outstanding Service
    • History
    • Diversity Statement
  • Education
    • NETCast Podcast Series
    • 2023 NET Medical Symposium
    • Regional NET Education
    • Virtual Programming Series
    • Upcoming Symposia
    • Conference Archives
    • NETMed Webinar Archives
    • About NETs
  • Research
    • Abstracts Library
    • Abstract Instructions
    • Research Grants
    • Grant Recipients
    • Grant Instructions
  • Guidelines
  • Resources
    • Grant Resources
    • NANETS Mentorship Program
    • Employment Postings
    • Clinical Trials
    • Member DirectoryMember Directory
    • NET Around the World
    • Patient Resources
    • Women in NETs
    • COVID-19 Resource Page
    • NANETS Collaboration Submission Form
  • News
    • NET eNews
    • Media
    • Endocrine-Related CancerEndocrine-Related Cancer
    • Photo Gallery
  • Membership
    • Member Login
    • Member Benefits
    • Member Categories
    • Join NOW
    • Code of Conduct
  • 2022

  • 2021

  • 2020

  • 2019

  • 2018

  • 2017

  • 2016

  • 2015

  • 2014

  • 2013

  • 2012

  • 2011

  • 2010

  • 2009

B01 – The Genomic Landscape of Small Intestine Neuroendocrine Tumors

Published in 2013 Listed under Basic Science

Download

Banck

B02 – Somatic Mutations in Inherited Pheochromocytomas and Paragangliomas

Published in 2013 Listed under Basic Science

Download

Fishbein

B03 – A Multi-Gene Transcript Blood Molecular Signature for the Detection and Treatment of Gut Neuroendocrine Tumors

Published in 2013 Listed under Basic Science

Download

Kidd

B04 – Specific Glycogen Synthase Kinase-3 Inhibition Suppresses Growth and Reduces the Neuroendocrine Tumor Markers in Neuroblastoma Cells

Published in 2013 Listed under Basic Science

Download

Kunnimalaiyaan

B05 – Gastric Inhibitory Polypeptide Receptor (GIPR): A Future Alternative to Somatostatin Type 2 Receptor Imaging and Treatment in Neuroendocrine Tumors?

Published in 2013 Listed under Basic Science

Download

Sherman

B06 – PI3K-AKT-mTOR Pathway Disregulation and its Correlation with Clinical Outcome in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus

Published in 2013 Listed under Basic Science

Download

Spada

B07 – A Primary Xenograft Model of Pancreatic Neuroendocrine Carcinoma Recapitulates Hallmark Features of the Disease

Published in 2013 Listed under Basic Science

Download

Wang

B08 – Aberrant Activation of DNA methyltransferase 1 (DNMT1) Mediated Global DNA Methylation and Implicates Sox/Wnt/β-Catenin Signaling Pathway in the Multiple Endocrine Neoplasm Type 1 (MEN1) Syndrome

Published in 2013 Listed under Basic Science

Download

Yuan

C01 – Czech Registery of Neuroendocrine Neoplasms (NEN)

Published in 2013 Listed under Clinical

Download

Barkmanova

C02 – A Systematic Literature Review on the Efficacy and Safety of Octreotide Long-Acting Repeatable Used at Higher than FDA-Approved Doses and/or Frequencies for Treatment of Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Download

Broder

C03 – Octreotide LAR in Patients with Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Case Series

Published in 2013 Listed under Clinical

Download

Byron

C04 – Lanreotide Autogel Significantly Improves Tumor Progression-Free Survival in Patients with Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors: Results of the CLARINET Study

Published in 2013 Listed under Clinical

Download

Caplin

C05 – Succinate Dehydrogenase Subunit B (SDHB) Immunohistochemistry Should Not Replace Clinical Genetic Testing for SDHx Mutations in Patients with Pheochromocytoma and Paraganglioma

Published in 2013 Listed under Clinical

Download

Fishbein

C06 – Cumulative Safety Experience of Telotristat Etiprate in Clinical Trials Supports Advancement to Phase 3

Published in 2013 Listed under Clinical

Download

Fleming

C07 – Unusual Case of a Hormone-Secreting SDHC Head and Neck Paraganglioma

Published in 2013 Listed under Clinical

Download

Ghayee

C08 – Moving 68Ga-labeled DOTA PET Imaging Agents Towards Approval

Published in 2013 Listed under Clinical

Download

Graham

C09 – A Phase I Study of Imatinib, Dacarbazine, and Capecitabine in Advanced Endocrine Cancers

Published in 2013 Listed under Clinical

Download

Halperin

C10 – Clinical Presentation and Management of Patients with Bone Metastases (BMet) from Neuroendocrine Tumors (NETs): Pooled Results from Two Institutional Databases

Published in 2013 Listed under Clinical

Download

Keiser

C11 – SDHB Pheochromocytoma and Paraganglioma Penetrance in a United States Population: An NIH Study

Published in 2013 Listed under Clinical

Download

King

C12 – Dose-Escalation of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET)

Published in 2013 Listed under Clinical

Download

Kulke

C13 – Patient-Reported Symptom Experiences Following Participation in a Study of Telotristat Etiprate for Patients with Carcinoid Tumor and Octreotide-Refractory Diarrhea

Published in 2013 Listed under Clinical

Download

Kulke

C14 – Comparison of 68Ga-DOTATATE (Ga) PET/CT with 111In-Octreotide (Octreoscan) SPECT in Somatastatin Positive Neuroendocrine Tumors (NET)

Published in 2013 Listed under Clinical

Download

Kumar

C15 – Patterns of Hepatic Metastases in Midgut Carcinoid: Diffuse Micrometastases and Disease Recurrence

Published in 2013 Listed under Clinical

Download

Liu

C16 – Neuroendocrine Tumors Arising in Meckel's Diverticula: Frequency of Advanced Disease Warrants Aggressive Management

Published in 2013 Listed under Clinical

Download

Lorenzen

C17 – 5-Fluorouracile/Capecitabine and Oxaliplatin (FOLFOX/XELOX) Suitable Treatments for Progressing G1-G2 Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Download

Marconcini

C18 – Neuroendocrine Tumors Treated with Lanreotide After First Line Treatment with Octreotide LAR: A Single Center Experience

Published in 2013 Listed under Clinical

Download

Marconcini

C19 – Recurrence After Complete Resection of Gastrointestinal (GNET) or Pancreatic Neuroendocrine Tumors (PNET): Single Center Analysis

Published in 2013 Listed under Clinical

Download

Marconcini

C20 – Single Center Experience of Everolimus (Ev) Treatment in Pretreated Metastatic Well Differentiated Gastrointestinal (GNET) and Pancreatic Neuroendocrine Tumors (PNET)

Published in 2013 Listed under Clinical

Download

Marconcini

C21 – Somatostatine Analogs (SSA) Treatment in Well Differentiated Gastroenteropancreatic NeuroendocrineTumors (GEP-NET): A Single Centre Experience

Published in 2013 Listed under Clinical

Download

Marconcini

C22 – Association of Urinary Bladder Paragangliomas with Germline Mutations in the SDHB and VHL Genes

Published in 2013 Listed under Clinical

Download

Martucci

C23 – Gallium-68 DOTATOC PET-CT for Localization of Primary Tumor in Patients with Metastatic Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Download

Menda

C24 – The Diagnostic Utility of Gallium-68 DOTATOC PET-CT in Patients with Suspected Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Download

Menda

C25 – Tumor Shrinkage in a Patient with Cushing's Disease Treated with Pasireotide: A Clinical Case Report

Published in 2013 Listed under Clinical

Download

Moloney

C26 – Comparison of Manual and Automatic Methods of Ki-67 Proliferation Index For Neuroendocrine Tumors: The Development and Validation of a Novel Digital Pathology Tool (Ki67Counter)

Published in 2013 Listed under Clinical

Download

Neltner

C27 – Safety and Quality-Of-Life (QOL) Assessments in the Open-Label, Multicenter, Phase 3b, Expanded Access Study of Everolimus in Patients with Advanced Neuroendocrine Tumors (NET)

Published in 2013 Listed under Clinical

Download

Pavel

C28 – Phase 1 Maximum-Tolerated Dose Study of Pasireotide LAR in Patients with Advanced Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Download

Phan

C29 – Efficacy and Safety of Everolimus in Patients with Advanced Low- or Intermediate-grade Pancreatic Neuroendocrine Tumors Previously Treated with Chemotherapy: A Subgroup Analysis of the RADIANT-3 Trial

Published in 2013 Listed under Clinical

Download

Pommier

C30 – Tumor Expression of VEGFA and Its Receptors and Clinical Outcomes in Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Download

Qian

C31 – A Phase I/II Dose Escalation Study of TKM-080301, a RNAi Therapeutic Directed Against PLK1, in Patients with Advanced Solid Tumors, with an Expansion Cohort of Patients with NET or ACC

Published in 2013 Listed under Clinical

Download

Ramanathan

C32 – Bronchial Carcinoid Tumors: A Single Institution Review

Published in 2013 Listed under Clinical

Download

Ramirez

C33 – Development of AminoMedixTM, a Kidney Protective Agent During Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Cancers

Published in 2013 Listed under Clinical

Download

Ranganthan

C34 – Survival in the Pre- and Post-Octreotide LAR Era in Carcinoid Syndrome Patients

Published in 2013 Listed under Clinical

Download

Ray

C35 – A Phase II Clinical and Translational Study of MK-2206 in Patients with Metastatic Neuroendocrine Tumors (NETs)

Published in 2013 Listed under Clinical

Download

Reidy

C36 – MIBG Avidity and Therapy in a Metastatic GI Neuroendocrine Tumor Patient Cohort

Published in 2013 Listed under Clinical

Download

Riff

C37 – Systemic Toxicity after Delayed Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Download

Riff

C38 – Is Renal Toxicity From Y-90 DOTATOC Dependent Upon Dose per PRRT Treatment?

Published in 2013 Listed under Clinical

Download

Sharma

C39 – Tumor Heterogeneity in Small Intestine Neuroendocrine Tumors Metastatic to the Liver

Published in 2013 Listed under Clinical

Download

Shi

C40 – Von Recklinghausen's Disease and Pheochromocytoma: A Ten-Year Experience

Published in 2013 Listed under Clinical

Download

Shinall

C41 – Retrospective Review of Patients with Metastatic High Grade Neuroendocrine Carcinoma of the Pancreas: Memorial Sloan-Kettering Cancer Center Experience (MSKCC)

Published in 2013 Listed under Clinical

Download

Shum

C42 – Capecitabine Plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Tumors (NETs): An Italian Multicenter Retrospective Analysis

Published in 2013 Listed under Clinical

Download

Spada

C43 – Increased Incidence of Second Malignancy in Patients with Neuroendocrine Tumours (NETs) of the Ileum and Colon (MGC)

Published in 2013 Listed under Clinical

Download

Stronge

C44 – Dosing Patterns for Octreotide LAR in Neuroendocrine Tumor (NET) Patients: NCCN NET Outcomes Database

Published in 2013 Listed under Clinical

Download

Strosberg

C45 – Exploratory Analysis of Early Response Signals Using Targeted Therapies for the Treatment of Advanced Carcinoid Tumor of the Kidney

Published in 2013 Listed under Clinical

Download

Subbiah

C46 – A Multicenter Phase II Trial Evaluating Safety and Efficacy of Activity Escalation with 177Lu-DOTA-TATE in Patients with Disseminated Neuroendocrine Tumors, Based on Detailed Dosimetry and Patient Selection

Published in 2013 Listed under Clinical

Download

Sundlov

C47 – Metastatic Recurrent Small Bowel "Carcinoid": The Role of Blood Neuroendocrine Transcript Analysis in Diagnosis and Management

Published in 2013 Listed under Clinical

Download

Teixeira

C48 – 68Ga-DOTATATE PET/CT Imaging for Evaluation of Neuroendocrine Tumors (NET): The Vanderbilt Experience

Published in 2013 Listed under Clinical

Download

Walker

C49 – Neuroendocrine Tumors (NETs) of Unknown Primary: Is Early Surgical Exploration and Aggressive Debulking Justifiable?

Published in 2013 Listed under Clinical

Download

Wang

C50 – The Diamagnetic Effects of Peritoneal Carcinomatosis in the Prognosis of Patients with Advanced Midgut Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Download

Wang

C51 – Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)

Published in 2013 Listed under Clinical

Download

Wolin

C52 – A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

Published in 2013 Listed under Clinical

Download

Wolin

C53 – Everolimus Plus Octreotide Long-Acting Repeatable (LAR) for the Treatment of Advanced Neuroendocrine Tumors (NET) Associated with Carcinoid Syndrome: Updated Overall Survival Results from RADIANT-2 Study

Published in 2013 Listed under Clinical

Download

Yao

C54 – The Immunohistochemical Expression of Islet 1 and PAX8 by Rectal Neuroendocrine Tumors Should be Taken into Account in the Differential Diagnosis of Metastatic Neuroendocrine Tumors of Unknown Primary Origin

Published in 2013 Listed under Clinical

Download

Zhou

NANETS

136 Everett Rd | Albany, NY 12205
(650) 7NANETS or (518) 465-4549 | staff@nanets.net

Member Login

Twitter Facebook LinkedIn
  • Privacy Policy
  • |
  • Site Map

Copyright ©2023 ADG. All Rights Reserved | Web Design & Development by ADG Creative, a division of ADG.
ADG is a certified Women Owned Business.